News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Dec 5, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 29, 2023

  Insmed To Present at the Nasdaq 49th Investor Conference
• Nov 8, 2023

  Insmed To Present at Two November Conferences
• Nov 3, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 2, 2023

  Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
• Oct 26, 2023

  Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
• Oct 26, 2023

  Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
• Oct 24, 2023

  Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
• Oct 12, 2023

  Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
• Oct 6, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 26, 2023

  Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
• Sep 8, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 6, 2023

  Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
• Sep 5, 2023

  INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
• Aug 4, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Aug 3, 2023

  Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
• Jul 20, 2023

  Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
• Jul 7, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jun 7, 2023

  Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
• Jun 6, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• May 22, 2023

  Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
• May 8, 2023

  Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
• May 5, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• May 4, 2023

  Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
• Apr 24, 2023

  Insmed to Host Investor and Analyst Event on May 8, 2023
• Apr 20, 2023

  Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
• Apr 6, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Mar 31, 2023

  Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
• Mar 24, 2023

  Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
• Mar 3, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Mar 1, 2023

  Insmed To Present at Two March Conferences
• Feb 23, 2023

  Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
• Feb 9, 2023

  Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
• Feb 7, 2023

  Insmed To Present at the SVB Securities Global Biopharma Conference
• Feb 3, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jan 20, 2023

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jan 6, 2023

  Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
• Jan 3, 2023

  Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
• Dec 6, 2022

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 30, 2022

  Insmed To Present at the Nasdaq 47th Investor Conference
• Nov 4, 2022

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 1, 2022

  Insmed To Present at Three November Conferences
• Oct 27, 2022

  Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
• Oct 27, 2022

  Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
• Oct 19, 2022

  Insmed Announces Strategic Financings Totaling $775 Million
• Oct 13, 2022

  Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
• Oct 7, 2022

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Oct 6, 2022

  Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
• Sep 7, 2022

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 6, 2022

  Insmed To Present at Two September Conferences

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download